Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precision BioSciences, Inc. (DTIL : NSDQ)

• Company Description    Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $1.71 Daily Weekly Monthly 20 Day Moving Average: 704,292 shares Shares Outstanding: 62.18 (millions) Market Capitalization: $106.32 (millions) Beta: 1.82 52 Week High: $14.38 52 Week Low: $1.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.33% -18.24% 12 Week -60.05% -55.10% Year To Date -76.89% -71.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 302 EAST PETTIGREW STREET SUITE A-100 - DURHAM,NC 27701 USA ph: 919-314-5512 fax: - jwong@bplifescience.com http://www.precisionbiosciences.com

• General Corporate Information    Officers Michael Amoroso - President; Chief Executive Officer and Director John Alexander Kelly - Chief Financial Officer Shane Barton - Vice President and Corporate Controller Derek Jantz, - Director Shalini Sharp - Director Peer Information Precision BioSciences, Inc. (CORR.) Precision BioSciences, Inc. (RSPI) Precision BioSciences, Inc. (CGXP) Precision BioSciences, Inc. (BGEN) Precision BioSciences, Inc. (GTBP) Precision BioSciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74019P108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 62.18 Most Recent Split Date: (:1) Beta: 1.82 Market Capitalization: $106.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.50 Price/Cash Flow: - Price / Sales: 1.04 EPS Growth vs. Year Ago Period: -39.39% vs. Previous Quarter: -21.05% Sales Growth vs. Year Ago Period: -79.71% vs. Previous Quarter: -47.67% ROE 03/31/22 - -44.19 12/31/21 - -34.78 09/30/21 - -41.63 ROA 03/31/22 - -18.86 12/31/21 - -13.15 09/30/21 - -14.61 Current Ratio 03/31/22 - 4.61 12/31/21 - 4.50 09/30/21 - 5.02 Quick Ratio 03/31/22 - 4.61 12/31/21 - 4.50 09/30/21 - 5.02 Operating Margin 03/31/22 - -39.10 12/31/21 - -26.49 09/30/21 - -26.91 Net Margin 03/31/22 - -39.10 12/31/21 - -26.49 09/30/21 - -26.91 Pre-Tax Margin 03/31/22 - -39.10 12/31/21 - -26.49 09/30/21 - -26.91 Book Value 03/31/22 - 1.14 12/31/21 - 1.50 09/30/21 - 1.70 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.04 12/31/21 - 0.03 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 3.44 12/31/21 - 2.65 09/30/21 - 0.00

Powered by Zacks Investment Research ©